Join

Compare · DMAC vs NVS

DMAC vs NVS

Side-by-side comparison of DiaMedica Therapeutics Inc. (DMAC) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DMAC and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $282.64B, about 984.1x DMAC ($287.2M).
  • Over the past year, DMAC is up 30.4% and NVS is up 29.0% - DMAC leads by 1.4 points.
  • DMAC has been more active in the news (12 items in the past 4 weeks vs 1 for NVS).
  • NVS has more recent analyst coverage (25 ratings vs 6 for DMAC).
PerformanceDMAC+30.42%NVS+29.02%
2025-06-11+0.00%2026-06-11
MetricDMACNVS
Company
DiaMedica Therapeutics Inc.
Novartis AG
Price
$5.29-1.03%
$152.25+2.80%
Market cap
$287.2M
$282.64B
1M return
-16.28%
+2.73%
1Y return
+30.42%
+29.02%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2018
News (4w)
12
1
Recent ratings
6
25
DMAC

DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Latest DMAC

Latest NVS